medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-19-22-29medsovet-5047Research ArticleИММУНОТЕРАПИЯ В ОНКОЛОГИИImmunotherapy in oncologyСтанет ли неоадъювантная иммунотерапия новой парадигмой лечения больных раком легкогоWill neo-adjuvant immunotherapy become a new paradigm in the treatment of lung cancer patientshttps://orcid.org/0000-0003-4469-502XЛактионовК. К.LaktionovK. K.

д.м.н., профессор, заведующий отделением химиотерапии №1 торако-абдоминального отдела 

115478, Россия, Москва, Каширское шоссе, д. 23

117997, Россия, Москва, ул. Островитянова, д. 1

Dr. of Sci. (Med), Professor, Head of the Department of Chemotherapy No.1 of the Thoraco-Abdominal Department

23, Kashirskoye sh., Moscow, 115478, Russia 1, Ostrovityanova Str., Moscow, 117997, Russia

lkoskos@mail.ruhttps://orcid.org/0000-0002-6244-4294БредерВ. В.BrederV. V.

д.м.н., ведущий научный сотрудник

115478, Россия, Москва, Каширское шоссе, д. 23

Dr. of Sci. (Med), Leading Researcher

23, Kashirskoye sh., Moscow, 115478, Russia

vbreder@yandex.ruhttps://orcid.org/0000-0002-0620-2696ЮдинД. И.YudinD. I.

к.м.н., старший научный сотрудник

115478, Россия, Москва, Каширское шоссе, д. 23

Cand. of Sci. (Med), Senior Researcher

23, Kashirskoye sh., Moscow, 115478, Russia

yudinden@mail.ruhttps://orcid.org/0000-0002-7817-8429СаранцеваК. А.SarantsevaK. A.

к.м.н., врач-онколог

115478, Россия, Москва, Каширское шоссе, д. 23

Cand. of Sci. (Med), Oncologist

23, Kashirskoye sh., Moscow, 115478, Russia

sarantsevaka@gmail.comhttps://orcid.org/0000-0002-5749-9864ЛактионоваЛ. В.LaktionovaL. V.

д.м.н., профессор кафедры восстановительной медицины

115533, Россия, Москва, ул. Высокая, д. 19, корп. 2

Dr. of Sci. (Med), Professor of the Department of Restorative Medicine, 

30, Volokolamskoe shosse, Moscow, 123182, Russia

Deputy General Director for Medical Affairs

bldg. 2, 19, Vysokaya Str., Moscow, 115533, Russia

laktionova@list.ruhttps://orcid.org/0000-0002-8967-7987АрдзинбаМ. С.ArdzinbaM. S.

к.м.н., врач

115478, Россия, Москва, Каширское шоссе, д. 23

Cand. of Sci. (Med), Oncologist, Oncological Department of Medicinal Methods of Treatment No. 17 (chemotherapeutic)

23, Kashirskoye sh., Moscow, 115478, Russia

merabii@mail.ruhttps://orcid.org/0000-0002-2154-3376РеутоваЕ. В.ReutovaE. V.

к.м.н., старший научный сотрудник

115478, Россия, Москва, Каширское шоссе, д. 23

Cand. of Sci. (Med), Senior Researcher

23, Kashirskoye sh., Moscow, 115478, Russia

evreutova@rambler.ruЕгороваА. В.EgorovaA. V.

к.м.н., доцент, профессор кафедры онкологии и лучевой терапии лечебного факультета

117997, Россия, Москва, ул. Островитянова, д. 1

Cand. of Sci. (Med), Associate Professor, Professor of the Department of Oncology and Radiation Therapy of the Medical Faculty

1, Ostrovityanova Str., Moscow, 117997, Russia

Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина; Российский национальный исследовательский медицинский университет имени Н.И. ПироговаРоссияFederal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation, Pirogov Russian National Research Medical UniversityRussian FederationНациональный медицинский исследовательский центр онкологии имени Н.Н. БлохинаРоссияFederal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian FederationRussian FederationМедицинский центр в КоломенскомРоссияFederal Medical and Biological Agency of Russia, CJSC «Medical center in Kolomenskoye»Russian FederationРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаРоссияFederal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian FederationRussian Federation2019041220190192229Copyright &#x00A9; Лактионов К.К., Бредер В.В., Юдин Д.И., Саранцева К.А., Лактионова Л.В., Ардзинба М.С., Реутова Е.В., Егорова А.В., 20192019Лактионов К.К., Бредер В.В., Юдин Д.И., Саранцева К.А., Лактионова Л.В., Ардзинба М.С., Реутова Е.В., Егорова А.В.Laktionov K.K., Breder V.V., Yudin D.I., Sarantseva K.A., Laktionova L.V., Ardzinba M.S., Reutova E.V., Egorova A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5047неоадъювантная иммунотерапиянемелкоклеточный рак легкогоингибиторы контрольных точекneoadjuvant immunotherapynon-small cell lung cancercheckpoint inhibitorsReferencesEberhardt W.E., Mitchell A., Crowley J., Kondo H., Kim Y.T., Turrisi A. 3rd, Goldstraw P., RamiPorta R. The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(11):1515-22. doi: 10.1097/JTO.0000000000000673.Eberhardt W.E., Mitchell A., Crowley J., Kondo H., Kim Y.T., Turrisi A. 3rd, Goldstraw P., RamiPorta R. The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(11):1515-22. doi: 10.1097/JTO.0000000000000673.Asamura H., Chansky K., Crowley J., Goldstraw P., Rusch V.W., Vansteenkiste J., et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;(10):1675–1684. doi: 10.1097/JTO.0000000000000678.Asamura H., Chansky K., Crowley J., Goldstraw P., Rusch V.W., Vansteenkiste J., et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;(10):1675–1684. doi: 10.1097/JTO.0000000000000678.Rami-Porta R., Bolejack V., Crowley J., Ball D., Kim J., Lyons G., et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;(10):990–1003. doi: 10.1097/JTO.0000000000000559.Rami-Porta R., Bolejack V., Crowley J., Ball D., Kim J., Lyons G., et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;(10):990–1003. doi: 10.1097/JTO.0000000000000559.Hilaris B.S., Gomez J., Nori D., Anderson L.L., Martini N. Combined surgery, intraoperative brachytherapy, and postoperative external radiation in stage III non-small cell lung cancer. Cancer. 1985;(55):1226–1231. doi: 10.1002/1097-0142(19850315)55:6<1226::aidcncr2820550614>3.0.co;2-6.Hilaris B.S., Gomez J., Nori D., Anderson L.L., Martini N. Combined surgery, intraoperative brachytherapy, and postoperative external radiation in stage III non-small cell lung cancer. Cancer. 1985;(55):1226–1231. doi: 10.1002/1097-0142(19850315)55:6<1226::aidcncr2820550614>3.0.co;2-6.Faber L.P., Kittle C.F., Warren W.H., Bonomi P.D., Taylor S.G. 4th, Reddy S., Lee M.S. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg. 1989;(47):669–675; discussion 676-667. doi: 10.1016/0003-4975(89)90115-x.Faber L.P., Kittle C.F., Warren W.H., Bonomi P.D., Taylor S.G. 4th, Reddy S., Lee M.S. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg. 1989;(47):669–675; discussion 676-667. doi: 10.1016/0003-4975(89)90115-x.Rosell R., Gomez-Codina J., Camps C., Maestre J., Padille J., Cantó A., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;(330):153–158. doi: 10.1056/NEJM199401203300301.Rosell R., Gomez-Codina J., Camps C., Maestre J., Padille J., Cantó A., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;(330):153–158. doi: 10.1056/NEJM199401203300301.Roth J.A., Fossella F., Komaki R., Ryan M.B., Putnam J.B. Jr., Lee J.S., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small-cell lung cancer. J Natl Cancer Inst. 1994;(86):673–680. doi: 10.1093/jnci/86.9.673.Roth J.A., Fossella F., Komaki R., Ryan M.B., Putnam J.B. Jr., Lee J.S., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small-cell lung cancer. J Natl Cancer Inst. 1994;(86):673–680. doi: 10.1093/jnci/86.9.673.Pisters K.M., Vallieres E., Crowley J.J., Franklin W.A., Bunn P.A. Jr, Ginsberg R.J., Putnam J.B. Jr., Chansky K., Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in earlystage non–small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010;(28):1843–1849. doi: 10.1200/JCO.2009.26.1685.Pisters K.M., Vallieres E., Crowley J.J., Franklin W.A., Bunn P.A. Jr, Ginsberg R.J., Putnam J.B. Jr., Chansky K., Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in earlystage non–small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010;(28):1843–1849. doi: 10.1200/JCO.2009.26.1685.Felip E., Rosell R., Maestre J.A., RodríguezPaniagua J.M., Morán T., Astudillo J., Alonso G. et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-smallcell lung cancer. J Clin Oncol. 2010;(28):3138–3145. doi: 10.1200/JCO.2009.27.6204.Felip E., Rosell R., Maestre J.A., RodríguezPaniagua J.M., Morán T., Astudillo J., Alonso G. et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-smallcell lung cancer. J Clin Oncol. 2010;(28):3138–3145. doi: 10.1200/JCO.2009.27.6204.Scagliotti G.V., Pastorino U., Vansteenkiste J.F., Spaggiari L., Facciolo F., Orlowski T.M., et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non–smallcell lung cancer. J Clin Oncol. 2012;(30):172–178. doi: 10.1200/JCO.2010.33.7089.Scagliotti G.V., Pastorino U., Vansteenkiste J.F., Spaggiari L., Facciolo F., Orlowski T.M., et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non–smallcell lung cancer. J Clin Oncol. 2012;(30):172–178. doi: 10.1200/JCO.2010.33.7089.Burdett S., Stewart L., Auperin A., Pignon J.P. Chemotherapy in non–small-cell lung cancer: an update of an individual patient data metaanalysis. J Clin Oncol. 2005; (23):924–925. author reply 925-926. doi: 10.1200/JCO.2008.17.7162.Burdett S., Stewart L., Auperin A., Pignon J.P. Chemotherapy in non–small-cell lung cancer: an update of an individual patient data metaanalysis. J Clin Oncol. 2005; (23):924–925. author reply 925-926. doi: 10.1200/JCO.2008.17.7162.Garon E.B., Hellmann M.D., Costa E.C., et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. J Clin Oncol. 2019 (suppl; abstr LBA9015). doi: 10.1200/JCO.2019.37.18_suppl.LBA9015.Garon E.B., Hellmann M.D., Costa E.C., et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. J Clin Oncol. 2019 (suppl; abstr LBA9015). doi: 10.1200/JCO.2019.37.18_suppl.LBA9015.Brahmer J., Borghaei H., Ramalingam S.S., Horn L., Holgado E., Pluzanski A., Burgioet M. et al. Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response. Conference: Proceedings: AACR Annual Meeting. 2019; March 29-April 3, 2019; Atlanta, GA. doi: 10.1158/1538-7445.AM2019-CT195.Brahmer J., Borghaei H., Ramalingam S.S., Horn L., Holgado E., Pluzanski A., Burgioet M. et al. Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response. Conference: Proceedings: AACR Annual Meeting. 2019; March 29-April 3, 2019; Atlanta, GA. doi: 10.1158/1538-7445.AM2019-CT195.Horn L., Gettinger S., Gordon M., Herbst R., Gandhi L., Felip E. et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer. 2018;(101):201-209. doi: 10.1016/j.ejca.2018.06.031.Horn L., Gettinger S., Gordon M., Herbst R., Gandhi L., Felip E. et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer. 2018;(101):201-209. doi: 10.1016/j.ejca.2018.06.031.Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012.Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012.Rusch V., Chaft J., Johnson B., Wistuba I., Kris M., Lee J. et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3). Journal of Clinical Oncology. 2018;36(15_suppl):8541-8541. doi: 10.1200/JCO.2018.36.15_suppl.8541.Rusch V., Chaft J., Johnson B., Wistuba I., Kris M., Lee J. et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3). Journal of Clinical Oncology. 2018;36(15_suppl):8541-8541. doi: 10.1200/JCO.2018.36.15_suppl.8541.Cascone T., William W.N., Weissferdt A., Leung C.H., Federico L., Haymaker C. et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. J Clin Oncol. 2019;(37S):ASCO#8504. doi: 10.1200/JCO.2019.37.15_suppl.8504.Cascone T., William W.N., Weissferdt A., Leung C.H., Federico L., Haymaker C. et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. J Clin Oncol. 2019;(37S):ASCO#8504. doi: 10.1200/JCO.2019.37.15_suppl.8504.Forde P.M., Chaft J.E., Smith K.N., Anagnostou V., Cottrell T., Hellmann M., Zahurak M., Yang S. et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976-1986. doi: 10.1056/NEJMoa1716078.Forde P.M., Chaft J.E., Smith K.N., Anagnostou V., Cottrell T., Hellmann M., Zahurak M., Yang S. et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976-1986. doi: 10.1056/NEJMoa1716078.Chaft J.E., Rusch V., Ginsberg M.S., Paik P.K., Finley D.J., Kris M.G., et al. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol. 2013;8(8):1084-1090. doi: 10.1097/JTO.0b013e31829923ec.Chaft J.E., Rusch V., Ginsberg M.S., Paik P.K., Finley D.J., Kris M.G., et al. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol. 2013;8(8):1084-1090. doi: 10.1097/JTO.0b013e31829923ec.Provencio M., Nadal E., Insa A., García Campelo R., Huidobro G., Domine M. et al. WCLC 2018 Abstract OA01.05. Available at: https://adisinsight.springer.com/trials/700281155.Provencio M., Nadal E., Insa A., García Campelo R., Huidobro G., Domine M. et al. WCLC 2018 Abstract OA01.05. Available at: https://adisinsight.springer.com/trials/700281155.Shu C., Grigg C., Chiuzan C., Garofano R., Patel V., Hernandezet S. et al. Neoadjuvant atezolizumab + chemotherapy in resectable nonsmall cell lung cancer (NSCLC). Journal of Clinical Oncology. 2018;36(15_suppl):8532-8532. doi: 10.1200/JCO.2018.36.15_suppl.8532.Shu C., Grigg C., Chiuzan C., Garofano R., Patel V., Hernandezet S. et al. Neoadjuvant atezolizumab + chemotherapy in resectable nonsmall cell lung cancer (NSCLC). Journal of Clinical Oncology. 2018;36(15_suppl):8532-8532. doi: 10.1200/JCO.2018.36.15_suppl.8532

The authors declare that there are no conflicts of interest present.